GLP1R and colitis: Collectively, these results suggest that endogenous GLP-1 ameliorates the course of DSS-induced colitis, most likely by altering genes involved in immune regulation, epithelial protection and repair; these actions would be preferable to the immunosuppressant mode of action characteristic of current therapies to treat IBD, which can expose the patients to adverse effects such as infection.